PRGO
Perrigo Co Plc Health Care Pharmaceutical Preparations Russell 3000
$15.78Close
$2.2BMarket cap
$8.83 – $19.3752-week range
Nov 4, 2026Next report · before the open
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 83 · stronger than 83% of stocks over 12 months
Cautions
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
19%
1wk
down 1.1%
price change
1mo
up 6.9%
price change
12-month return
down 18%
market up 11% ·
its own down 31%
F-score
4 / 9
Weak
Altman Z
-0.06
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
0.7×
price / book
Earnings yield
down 21.4%
EBIT / enterprise value
Cheaper than
59%
of the market · around average
Revenue growth
down 3%
year on year
EPS growth
—
latest quarter
Sales growth
down 3%
latest quarter · +4 pts
ROE
down 39%
return on equity
Free cash margin
up 3%
$145.1M FCF
D/E
1.23
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- profitability slipped from last year
- took on more long-term debt
- issued more shares
- gross margin narrowed
- generating cash from operations
- profits backed by cash
- short-term liquidity improved
- assets working harder
Trade setup
ATR%
4.0%
$0.62 a day · 2×ATR $14.53
RS
83 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.3×
vs 50-day average
Up/down volume
1.25
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Revenue shrinking Revenue fell 2.8% over the year, from $4.4B to $4.3B.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+17% vs market2 sessions after results
Financials
- Gross 35%
- Net -34%
- Free cash 3%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $4.1B | $4.1B | $4.5B | $4.7B | $4.4B | $4.3B |
| Gross margin | 37% | 34% | 33% | 36% | 35% | 35% |
| Operating income | $265.2M | $410.4M | $78.9M | $151.9M | $112.9M | -$1.1B |
| Net income | -$162.6M | -$68.9M | -$140.6M | -$12.7M | -$171.8M | -$1.4B |
| Net margin | -4% | -2% | -3% | -0% | -4% | -34% |
| Earnings per share | -$1.19 | -$0.52 | -$1.05 | -$0.09 | -$1.25 | -$10.29 |
| Free cash flow | $465.8M | $4.2M | $210.9M | $303.8M | $244.6M | $145.1M |
| Free cash margin | 11% | 0% | 5% | 7% | 6% | 3% |
| Cash | $631.5M | $1.9B | $600.7M | $751.3M | $558.8M | $531.6M |
| Long-term debt | $3.5B | $2.9B | $4.1B | $3.6B | $3.6B | $3.6B |
| Shareholders' equity | $5.7B | $5.2B | $4.8B | $4.8B | $4.3B | $2.9B |
| Shares outstanding | 133.10m | 133.80m | 134.70m | 135.50m | 136.50m | 137.60m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 27, 2026 | 39d |
| May 6, 2026 | Quarterly ↗ | Mar 28, 2026 | 39d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 5, 2025 | Quarterly ↗ | Sep 27, 2025 | 39d |
| Aug 6, 2025 | Quarterly ↗ | Jun 28, 2025 | 39d |
| May 7, 2025 | Quarterly ↗ | Mar 29, 2025 | 39d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 6, 2024 | Quarterly ↗ | Sep 28, 2024 | 39d |
| Aug 2, 2024 | Quarterly ↗ | Jun 29, 2024 | 34d |
| May 7, 2024 | Quarterly ↗ | Mar 30, 2024 | 38d |
| Feb 27, 2024 | Annual ↗ | Dec 31, 2023 | 58d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Regulation FD ↗ |
| Aug 5, 2026 | Results ↗ |
| Jul 6, 2026 | Director or officer change ↗ |
| Jun 30, 2026 | Director or officer change · Regulation FD ↗ |
| Jun 8, 2026 | Director or officer change · Regulation FD ↗ |
| May 6, 2026 | Results ↗ |
| May 5, 2026 | Director or officer change · Shareholder vote ↗ |
| Apr 30, 2026 | Acquisition or disposal · Regulation FD ↗ |
| Apr 22, 2026 | Results · Regulation FD ↗ |
| Mar 23, 2026 | Material agreement · New obligation ↗ |
| Feb 26, 2026 | Results ↗ |
| Nov 5, 2025 | Results · Regulation FD ↗ |